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Executive Summary
Involuntary treatment is a lengthy legal process through which an individual that is
deemed to be a danger to themselves or to others is forced to receive psychiatric treatment
against their will. Often, involuntary treatment utilizes a medication called a long-acting
injectable antipsychotic (LAI). With the rise of implicit bias awareness as of late, there has been
new research showing that Black patients receive LAIs at disproportionate rates compared to
White patients. There has not been research, however, to show the impact of diversity, equity,
and inclusion (DEI) training of healthcare providers on the utilization rate of LAIs among the
different races. This study used data collected from UK HealthCare to analyze the rate of LAI
utilization and schizophrenia diagnosis among different demographics pre– and post–DEI
training. Although a statistically significant difference between the two time periods was not
found among White and Black patients, this study still highlighted a disproportionate rate of LAI
utilization and schizophrenia diagnosis for Black patients. The results of this study show that
DEI training in its current form may not be effective, and through involuntary treatment, the
government may be perpetuating implicit biases.

Background
No area of medicine has such a harsh history as mental illness. The history of mental
health treatment is riddled with procedures such as electroshock therapy, ice pick lobotomies,
and insulin coma therapy. Today, many healthcare professionals recognize the cruelty of these
past treatments and now these practices are either not used at all or are altered significantly for
safer patient outcomes. There is, however, one aspect of mental health treatment that has
continued to this day: involuntary treatment. Involuntary treatment is known by many names,
such as civil or involuntary commitment, involuntary hospitalization, or forced treatment, and
these terms are commonly used interchangeably.
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Involuntary Treatment
Involuntary treatment is still used today in situations when individuals with mental illness
are deemed to be a danger to themselves or to others. The main difference in today’s age is
that involuntary treatment is a lengthy legal process, mainly due to the Community Mental
Health Centers Act signed by John F. Kennedy in 1963 and three legal cases: Lake v. Cameron
in 1966, O’Connor v. Donaldson in 1975, and Addington v. Texas in 1978 (Fariba & Gupta,
2021). Involuntary treatment doesn’t only have to take place in a hospital (also known as
inpatient); it can also be outside of the hospital (also known as outpatient) through an
involuntary outpatient civil commitment (OPC). Of course, every step of the process (for both
inpatient and outpatient involuntary treatment) involves judicial surveillance, and appeal
opportunities are required (Jacobsen, 2012). Many people argue that involuntary treatment
reduces serious acts of violence, but data has yet to show this; the idea that patients with
serious mental illness are violent is not always the case (Swartz et al., 2016). Involuntary
treatment does, however, improve treatment adherence and related outcomes (Swartz et al.,
2016). Although it varies from state to state, generally an involuntary treatment order is brought
before a judge just like any other court case. This process was observed personally at Eastern
State Hospital in Lexington, KY. Prosecuting attorneys (commonwealth attorneys in Kentucky)
and a defending attorney (usually a public defender) ask the attending psychiatrist questions
and argue whether involuntary treatment should be used. Two psychiatrists must sign an order
for involuntary treatment for it to be considered by a judge. Ultimately, it is up to the judge to
decide whether a patient will be forced to receive medical treatment, but the patient does have
an opportunity to speak on their own behalf. An involuntary treatment order must include the
medications that will be forced. It is not just a blanket forced medication order for all
medications; it’s specific to the medication(s) discussed during the court trial and agreed upon
by the judge. Often, these forced medication orders are crafted in a stepwise fashion, meaning if
the patient refuses to take an oral option, the treating psychiatrist can then progress to another
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specific medication that can be administered into the muscle. These forced medication orders
also often include forced lab orders so that drug levels and other labs can be measured to
ensure therapy safety.

Long-Acting Injectable Antipsychotics
Involuntary treatment often includes the utilization of long-acting injectable
antipsychotics (LAIs) which are medications that are administered intramuscularly (directly into
the muscle, like how many vaccines are administered) every four weeks, instead of a daily oral
medication. Antipsychotics are a class of psychotropic medications (meaning they affect a
person’s mental state) that act on receptors in the brain to manage delusions, hallucinations,
paranoia, or other symptoms commonly associated with schizophrenia, acute mania, or other
serious mental illnesses (Chokhawala & Stevens, 2021). Commonly prescribed LAIs include
Abilify Maintena (generic name: aripiprazole), Invega Sustenna (generic name: paliperidone),
Haldol Decanoate (generic name: haloperidol), Risperdal Consta (generic name: risperidone),
among others. LAIs are thought to increase medication adherence in a population that
historically has had low adherence rates since these medications are administered every four
weeks instead of requiring daily oral intake (Chaudhari, et al., 2017). Evidence has yet to
confirm this fact, but it has been determined that “LAIs are at least as effective as oral
[antipsychotics] in the treatment of psychotic disorders” (Manchanda, et al., 2013). As with any
medication, there are possible side effects to LAIs. The most common adverse drug event
reported is pain at the injection site; however, majority of evidence finds that “patients tolerate
[LAIs] relatively well” (Zolezzi, et al., 2021). There are potential risks associated with the longterm use of antipsychotics (such as weight gain, high cholesterol, and high blood sugar), but
these risks can be monitored and adjusted for before they become permanent lifelong issues.
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Implicit Biases in Healthcare
Mental health (much like many other areas of healthcare) has seen a shift in recent
years as implicit bias awareness has come to the forefront. “Today, the biased provision of
health services is a well-documented barrier to health for marginalized populations” and mental
health services are no exception (Merino, et al., 2018). Implicit biases impact patients’ mental
healthcare in multiple ways. One way is by impacting a patient’s access to mental health care.
Since mental health treatment is commonly a one-on-one interaction, “there is perhaps a
greater potential for implicit bias among mental health professionals that prevents certain
groups from accessing some mental health services” (Merino, et al., 2018). Implicit biases can
also play a role in how certain behaviors are perceived. For example, a Black man who is
vigilant in everyday life for fear of racial profiling by police officers, could be interpreted as being
paranoid (Merino, et al., 2018). The diagnosis of certain illnesses can also be impacted by
implicit biases. Despite the standardized diagnostic criteria provided by the Diagnostic and
Statistical Manual of Mental Disorders, Fifth Addition (known more commonly as the DSM-5),
mental health providers “are more likely to underdiagnose affective [or mood] disorders and
overdiagnose psychotic disorders [such as schizophrenia] among patients from marginalized
groups compared with the majority” (Merino, et al., 2018). Implicit bias exists among all
healthcare providers, mental health providers included. These biases can significantly impact a
patient’s care and perpetuate mental health disparities.

Problem Statement
Long-acting injectable antipsychotics may be more likely to be utilized in specific subsets
of the population, which is concerning, especially since they are commonly used as a part of
court-ordered involuntary treatment. This study attempts to answer where or not there is a
difference in the rate of LAI utilization among White and Black patients pre– and post–DEI
training. This will (to the author’s knowledge) be the first study conducted in such a fashion.
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Literature Review
Patient Perceptions
Even though LAIs are thought to improve patient adherence, “LAI prescription rates in
clinical practice in most Western countries are low” (Blackwood et al., 2020). The largest
potential barriers to LAI usage are patients’ perceptions and attitudes (Blackwood et al., 2020).
Blackwood et al. performed an analysis in patients with schizophrenia to assess factors that
determine patient’s preference for an LAI or an oral antipsychotic. What is interesting from this
analysis is how the results look when broken down into different races. “Preference for LAI was
highest among White (84.2%) followed by other racial groups (71.2%) and Black (57.7%)
patients” and “in the logistic regression analysis, race (White) … showed a significant
association (p<0.001) with patient preference for LAIs” (Blackwood et al., 2020). This study
shows that White patients are more likely to prefer LAIs over Black patients. This is likely due to
the (understandable) mistrust Black/African American patients have with medicine. “Thirty-nine
percent of Black patients said they have encountered discrimination in the medical setting at
least somewhat often, and 31 percent said they experienced discrimination very often. Only 27
percent of Hispanic patients said they experience discrimination somewhat often, and more than
half of White patients said discrimination against them happened only rarely” (Heath, 2020).
Despite Black patients not preferring LAIs, and having more mistrust in medicine, there is
evidence that shows they receive LAIs at disproportionate rates compared to White patients.

Unequal Use of LAIs Between Races
While Blackwood et al. attempted to find a difference in preference for LAIs over oral
antipsychotics, Soleman, et al. (2017) conducted a study determining whether different
ethnicities and age groups receive LAIs equally. This study found no statistically significant
impact of ethnicity on whether a patient received an LAI (chi-square=0.88, df=3, p=0.831)
(Soleman, et al., 2017). There are significant limitations to this study, though. First, the authors
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mention that the healthcare system that from which the data are derived from does not have a
separate racial category for the Latino population. This could have a significant impact on the
generalizability of this information to specific racial groups. This study was also conducted at a
single site in Los Angeles County, California, thus making the generalizability to other
healthcare systems even lower. The authors also touched on the fact that their “findings are in
disagreement with previous studies” (Soleman et al., 2017).
Although Soleman et al. found no association between race and the utilization of LAIs,
there have been studies that have demonstrated this difference. Aggarwal et al. conducted a
study to determine if “racial minorities are disproportionately prescribed long-acting injectable
antipsychotic drugs” (2012). Their study found that “White patients were significantly less likely
to receive long-acting antipsychotic prescriptions than minority patients (OR=0.52, p<0.007);
i.e., nonwhites were 1.89 times more likely to receive such drugs” (Soleman et al., 2012). This
fact is compounded when you consider that other patient demographics (age, gender, and
comorbid diagnoses) were not correlated with the likelihood of a patient receiving an LAI
(Soleman et al., 2012). It is important to note that this study was also conducted at a single site
and the racial information collected was not uniform across all patients (some patients selfidentified their race, while others were assigned a race by the clinician). It is possible that the
difference in LAI utilization among races could be related to perceived nonadherence; “racial
and ethnic minorities … may be perceived as at higher risk for nonadherence and in need of
long-acting injectable prescription” (Soleman et al., 2012).

Rise of Diversity, Equity, and Inclusion Training in Healthcare
Although diversity, equity, and inclusion (DEI) training has generally been on the rise for
the past decade, recent events have greatly impacted its popularity. A few academic medical
centers (AMC) initiated unconscious bias training for future healthcare professionals in 2019
likely in response to the American Medical Association (AMA) establishing the AMA Center for
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Health Equity (Robeznieks, 2020). The impact of implicit biases did not make national news until
May of 2020 when an online video surfaced of Minneapolis police officer Derek Chauvin placing
his knee on the back of George Floyd’s neck as he arrested him, resulting in Mr. Floyd’s death
(Hill, et al., 2020). This horrific event placed a great emphasis on racial inequality in America. At
the same time, the COVID-19 pandemic was bringing to light many differences in healthcare
among racial groups. As a matter of fact, in June of 2020, “Black people [were] dying from
COVID at roughly the same rate as White people more than a decade older” (Ford, et al., 2020).
This is truly when the topic of implicit biases in healthcare became a hot topic. Many AMCs,
such as the University of Kansas and the University of Maryland, began offering unconscious
bias training in June and July of 2020 (KU Medical Center Office for Diversity, Equity and
Inclusion; University of Maryland School of Medicine). Johns Hopkins School of Medicine first
offered anti-bias training in September of 2020 to “teach students and trainees how to address
unconscious bias and recognize structural racism in their treatment of patients and their
interactions with colleagues” (Nitkin, 2020). This was shortly followed by the Association of
American Medical Colleges (AAMC) releasing their framework for addressing racism in
academic medicine in October 2020 (Redford, 2020). Google trends also show that the search
term “unconscious bias” has had two peaks over the last five years: the week of June 7th and
the week of October 25th, both in 2020 (see attached Supplementary Material #1).

Conclusion of Current Literature
There is a wide array of available literature on the possible racial disparities in the
utilization of LAIs. Studies have shown a correlation between race and LAI utilization, while
others haven’t, despite the evidence that White patients prefer LAIs over non-White patients.
This study will supplement the available information, while also providing a starting point for
future research into this issue.
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Hypothesis
Given the recent rise in implicit bias awareness, there is likely going to be differences
among the patient populations included in this analysis. Historically, “Black Americans are
disproportionately diagnosed with schizophrenia and experience worse objective functional
outcomes (e.g. hospitalizations) than their White counterparts” (Nagendra, et al., 2020).
Therefore, it is expected that Black Americans receive LAIs disproportionately more often than
White Americans. Alternatively, if no difference was seen, then it can be said that LAIs are being
utilized equally among races. It is also expected that after DEI training, the rate of LAI utilization
should be more similar among the different racial groups. If there is no difference, then it would
appear that DEI training has no impact on the prescribing patterns of LAIs among racial groups.

Data
Data for this analysis were collected from information available through the University of
Kentucky’s Center for Clinical and Translational Science i2b2 tool. “The i2b2 (informatics for
integrating biology and bedside) query tool allows one to retrieve de-identified, aggregate
counts of patient populations that match a given criteria. I2b2 provides a framework that allows
clinical claims data to be warehoused and searched based on specific inclusion and exclusion
criteria selected by the user” (University of Kentucky Center for Clinical and Translation
Science). This analysis included every patient that received specific LAIs between a year prior
and after a specified date, within the UK HealthCare system. Unfortunately, the specific date of
when the University of Kentucky implemented its version of DEI training is unavailable, but
considering the literature, October 15th, 2020, appears to be an appropriate estimate. “Time
Period One” refers to the period prior to DEI training (October 15th, 2019, through October 15th,
2020), while “Time Period Two” refers to the period after DEI training (October 16th, 2020,
through October 16th, 2021).
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The i2b2 tool provided patient demographics for every patient who received specific
LAIs. This information included the patient’s race, gender, and age. Data on the prevalence of
schizophrenia diagnosis within UK HealthCare was also provided. This secondary analysis was
conducted utilizing ICD-10 codes F20-F29, which are the ICD-10 codes associated with the
spectra of schizophrenia illnesses. ICD-10 codes are used by the Centers for Medicare and
Medicaid Services (CMS) for billing purposes and each disease state has a specific assigned
code. All F20-F29 ICD-10 diagnoses were included (not just in the patients who received an
LAI), and the results were also broken down by race, gender, and age.

Research Design
Not Human Research Determination
The federal definition of a human subject is “a living individual about whom an
investigator conducting research obtains (i) information or biospecimens through intervention or
interaction with the individual and uses, studies, or analyzes the information or biospecimens; or
(ii) obtains, uses, studies, analyzes, or generates identifiable private information or identifiable
biospecimens” [45 CFR 46.102(e)(1)]. Since the i2b2 tool doesn’t provide direct access to
patient identifiers, nor does it allow for the re-identification of individuals, the University of
Kentucky Institutional Review Board determined that this analysis did not include data meeting
the federal definition of human subject research, and thus did not require IRB approval.

Variable Selection
The first variable collected (the dependent variable) was whether an LAI was used. This
was provided as a total count of how many patients received each specific LAI. The LAIs
included were slightly limited due to UK HealthCare’s formulary, but four commonly encountered
LAI antipsychotics were able to be analyzed: Haldol Decanoate, Abilify Maintena, Invega
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Sustenna, and Risperdal Consta. The independent variables included the demographics that
were analyzed: age, race, and gender (which were all categorical variables).

Statistical Analysis
The descriptive statistics provided by this analysis indicate a snapshot of the patient
demographics receiving LAIs, but this information is not applicable to drawing conclusions about
the entire population. Nonetheless, this analysis still provides valuable information and can
serve as a starting point for a very important issue in healthcare. To determine if there was a
difference in the proportion of LAIs used among White and Black patients between the two time
periods, a Pearson’s chi-square test was conducted. A p-value<0.05 was considered
statistically significant.

Results
Primary Analysis
In total, 80 patients received a LAI during Time Period One (10/15/19 – 10/15/20), while
123 patients received one during Time Period Two (10/16/20 – 10/16/21). In both time periods,
Invega Sustenna was the most administered LAI, followed by Abilify Maintena. In total, during
Time Period One, 13.75% of LAIs administered were in Black or African American patients,
compared to 19.51% for Time Period Two. There was not a statistically significant difference
between the two time periods when comparing the rate of LAI usage between White and Black
patients (p-value=0.26, df=1). The results of the total racial breakdown are below, while the
results of gender can be found under Supplementary Material #2.
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Secondary Analysis
Overall, 1,669 patients were given an ICD-10 code associated with schizophrenia during
Time Period One, compared to 1,755 patients during Time Period Two. Majority of patients with
such an ICD-10 code diagnosis were White, representing 78.13% for Time Period One and
77.95% for Time Period Two. Black or African American patients made up 19.65% and 19.89%
for each time period, respectively. The results of the racial breakdown are below, while the
results for gender can be found under Supplementary Material #3.
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Discussion
Primary Analysis
Although there was not a statistically significant difference in the utilization of LAIs
among White and Black patients between Time Period One and Time Period Two, these results
still show high rates of Black patients receiving LAIs. According to the United States Census
Bureau, 8.5% of Kentucky’s population is Black or African American alone (2021); however, in
both time periods, Black/African American patients account for more than 8.5% of LAIs
administered (13.75% for Time Period One; 19.51% for Time Period Two). It’s interesting to
note that this percentage increased between the two time periods (even though it wasn’t a
statistically significant increase). This is surprising since one would expect that DEI training
would cause the rate of LAI administration to be more equal among different races. It is
possible, however, that DEI training could explain this increase. “Evidence shows that
organizational diversity and inclusion initiatives (DIIs) are frequently ineffective, or worse, that
they lead to worse diversity and inclusion related outcomes” (Temkin & Itembu, 2020). While
slightly unexpected from a DEI training perspective, the data does show that Black/African
American patients are administered LAIs at a disproportionate rate as compared to their White
counterparts. This might be due to unconscious bias on the part of medical professionals. This
study does not show that DEI training changes the impact of unconscious biases.

Secondary Analysis
When considering the diagnosis rate of schizophrenia, this study agrees with previous
literature. Black/African American patients represented 19.65% and 19.89% of all schizophrenia
diagnoses in Time Period One and Time Period Two, respectively, despite Black/African
Americans only representing 8.5% of Kentucky’s population (United States Census Bureau,
2021). The difference in the diagnosis of schizophrenia for Black patients has long been
researched. One study found that “even after controlling for other significant demographic and
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clinical characteristics, African Americans were more than three times as likely to be diagnosed
with schizophrenia than Euro-Americans” and the authors concluded that “to date, there are no
empirically verified explanations determining why African Americans are overrepresented in
having a schizophrenia diagnosis” (Schwartz & Blankenship, 2014). The authors propose a
couple of theories (clinician bias, underdiagnosis of other mental illnesses, among others), but
biological differences are not considered to be an explanation (Schwartz & Blankenship, 2014).

COVID-19
A major limitation of this study is the impact of the coronavirus pandemic. The first case
of COVID-19 was reported in the United States on January 20th, 2020, and by March 11th, 2020,
the World Health Organization declared COVID-19 a pandemic (Centers for Disease Control
and Prevention). Shortly after, many states began to shut down to prevent the spread of
COVID-19 and hospitals began limiting non-COVID admissions. This has a great impact on the
data for both Time Period One and Time Period Two in a multitude of ways. Hospitalization
rates were not steady and could have a large effect on the already small dataset. COVID-19
could also have influenced the rate of LAI utilization considering the rise of mental health
illnesses as the pandemic continued. This weakens the validity of the entire analysis; however,
it could not have been minimized. Ideally, data would be collected from a period when COVID19 did not have any impact; however, the rise of unconscious biases in healthcare and the
coronavirus pandemic occurred almost simultaneously. This complicates this analysis and likely
any future analyses as well.

Limitations
Beside the impact of COVID-19, there are other limitations to this analysis. First, while
the i2b2 tool is a great resource for data collection, it is limited to the information it provides. The
i2b2 tool was not able to provide whether these LAIs were administered under a forced
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medication order, however, it did provide insight into which demographics are receiving these
injections. Also, to avoid reidentifying patients, all counts provided by the i2b2 tool included a
±3. If any count was less than three patients, the result returned only read ±3. Any such result
was included as a count of zero in this analysis, which could have an impact on the statistical
analyses, especially considering how small the sample sizes for LAI utilization were. In other
words, it is possible that races that represent a small percentage of Kentucky’s population (i.e.,
Native Hawaiian, Native American, etc.) were not included in the statistical analyses because
less than three patients who identified as these races received an LAI. Secondly, this analysis
doesn’t lend to conclusions being drawn about the entire population as not enough data were
provided to run a regression analysis. In an ideal situation, enough data would have been
available to evaluate whether there is a correlation between the receival of an LAI and a
patient’s race. This could be conducted via a binomial logistic regression since the dependent
variable (whether or not an LAI was used) is binomial via a multiple regression approach. In an
even more ideal situation, hypothesis testing would be used to determine the reliability of this
regression. Even if these conclusions were able to be drawn, it would likely be difficult to meet
power. This study only included a small sample size at a single center. This analysis was also
limited to which LAIs could be included due to UK HealthCare’s hospital formulary. A formulary
is a list of medications available for use at a hospital. This is not to say that medications that are
not on formulary cannot be used (for example, Abilify Maintena is not on UK HealthCare’s
formulary, but was the second most administered LAI). Given the extensive psychiatric
treatment provided by Good Samaritan Hospital (a community hospital owned by UK
HealthCare), it is likely that the preference for formulary vs. non-formulary medications can be
ignored, but there are limitations to which LAIs were used in this analysis (for example, there
were no administrations of Invega Trinza, another FDA-approved LAI). However, the four LAIs
included in this analysis are very commonly prescribed and could all be utilized in a forced
treatment order. Another limitation of this study is that it cannot be fully determined if the
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University of Kentucky had finished DEI training among all healthcare providers by October 16th,
2020. Although supported with evidence from literature, a specific training date could not be
determined, and the date selected was somewhat arbitrary. It also may have been beneficial to
include a “washout period” (perhaps a span of approximately six months between the two time
periods) to address this limitation more appropriately; however, this would have greatly reduced
the available data for Time Period Two as it would be approaching present time.

Conclusion
This analysis adds to the literature showing that Black/African American patients are
disproportionally being treated with LAIs, as well as diagnosed with schizophrenia. While this
could be because schizophrenia is more common in Black/African American patients, there has
been significant research that shows how clinicians’ unconscious biases impact their diagnoses,
especially in the realm of mental health. Although DEI training’s purpose is to curb these implicit
biases, this study does not show this to be the case. Future studies should continue analyzing
the impact of DEI training, ideally when the impact of COVID-19 is not as high.

Recommendations
The results of this study shed light on an already dim area of medicine. Too long, mental
health treatment has been plagued by mistrust and stigma. These issues are only compounded
when one considers that patients can be forcibly required to receive treatment by the
government. If future studies continue to conclude that Black/African American patients are
being diagnosed/treated for schizophrenia at disproportionately higher rates, then the
government could be unknowingly perpetuating these biases. This is not to say that
forced/involuntary treatment should not be utilized (there are numerous studies to show its
benefit), but that it should be used with great caution. Although mental health diagnoses can be
greatly impacted by a provider’s unconscious biases, there have been many changes to the
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DSM over the years to reduce this impact. The DSM should continue to change as more
evidence continues to be published. There also needs to be significant changes to the DEI
training provided to healthcare professionals. To truly extinguish the impact of implicit biases,
organizations need to “[target] training to different audiences, [re-engineer] hiring practices, [and
use] technology and behavioral science to reduce bias in performance evaluations” (Chang et
al., 2019). In other words, DEI training by itself is not enough to minimize implicit biases among
healthcare providers; it requires a multitude of changes throughout the entire healthcare
organization. If it is determined that after these changes these disproportions still exist, then the
future of involuntary treatment for mental illnesses should be re-evaluated to maximize patient
experience and minimize implicit biases.
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